Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.09.2016 | short review | Ausgabe 3/2016 Open Access

memo - Magazine of European Medical Oncology 3/2016

Reversal of direct oral anticoagulants in hemophilia treatment

ASH meeting 2015

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 3/2016
Autoren:
MD Clemens Feistritzer, Stefan Schmidt

Summary

During the 57th annual meeting of the American Society of Hematology 2015 in Orlando, Florida, various aspects in the field of hemostaseology were presented. The Choosing Wisely® campaign pointed out the importance of the critical use of diagnostic tools to rule out pulmonary embolism and questioned the relevance of thrombophilia testing in women undergoing routine infertility evaluation. Furthermore, the approval of idarucizumab, a specific antidote for the reversal of the anticoagulant effects of the direct thrombin inhibitor dabigatran, was highlighted. Finally, hemophilia specialists awaited the results of the SIPPET Trial, which were presented for the first time during the plenary session. Replacement therapy of previously untreated hemophilia A patients with plasma-derived factor VIII containing von Willebrand factor resulted in a lower incidence of inhibitors compared with patients treated with recombinant factor VIII.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2016

memo - Magazine of European Medical Oncology 3/2016 Zur Ausgabe